Today's Edition
A. SREENIVASA REDDY (ABU DHABI)
Burjeel Holdings reported a net profit of Dh227 million, excluding one-off items, for the first half of 2026, representing an increase of 97.4% year-on-year.
Revenue increased 4.4% to Dh2.794 billion, while EBITDA excluding one-off items rose 24.6% to Dh517 million. The group recorded more than 3.7 million patient visits during the period, an increase of 9.9% from a year earlier.
Speaking to Aletihad, Dr Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings, said the one-off items excluded from EBITDA and net profit related to impairment charges for the PhysioTherabia business in Saudi Arabia and the planned relocation of Burjeel Hospital for Advanced Surgery in Dubai.
In the second quarter, revenue rose 3.7% year-on-year to Dh1.455 billion, while EBITDA excluding one-off items increased 35% to Dh316 million. The EBITDA margin improved to 21.7% from 16.7% a year earlier.
Second-quarter net profit excluding one-off items increased 124.7% to Dh171 million, with the net profit margin rising to 11.7% from 5.4%. Patient visits grew 12.4% year-on-year during the quarter.
Dr Vayalil said the regional situation had resulted in a temporary moderation in high-acuity elective surgeries around March, but patient activity recovered progressively during the second quarter.
Outpatient footfall increased 12.5% in the second quarter and 10% in the first half, while inpatient volumes rose 8.4% and 7.2%, respectively. The growth was supported by the ramp-up of recently opened facilities and sustained demand for specialties including oncology, cardiology and gastroenterology.
“The acceleration in activity during the second quarter reinforced our confidence in the underlying demand for high-quality, specialised healthcare across the region,” Dr Vayalil said.
Hospitals accounted for 89% of group revenue during the first half. Revenue outside the hospital segment was generated by the group’s medical centres and wider outpatient healthcare network, which provide family medicine, paediatrics, women’s health, fertility, advanced diagnostics, oncology, cardiology and gastroenterology services.
Dr Vayalil said the medical centres continued to record healthy growth, supported by rising utilisation at established facilities and recently opened centres.
“This provides the group with a broader and more diversified revenue base across its integrated healthcare platform,” he said.
Burjeel Medical City completed 19 liver and kidney transplants during the first half. The hospital’s multi-organ transplant programme, which includes complex liver and deceased-donor kidney procedures, has completed 86 transplants since its inception.
Burjeel’s net leverage remained stable at 1.8 times as of June 30. The group completed a $500 million senior unsecured sukuk issuance on July 1 and used the proceeds primarily to refinance existing debt.
Following the refinancing, Burjeel fully repaid a Dh1.598 billion term loan and reduced the amount drawn under its First Abu Dhabi Bank revolving credit facility by Dh209 million.
Outstanding debt stood at Dh1.915 billion as of July 31, comprising Dh1.837 billion under the sukuk and Dh78 million drawn under the revolving credit facility. The group also had Dh672 million in undrawn committed facilities.
“The first half of 2026 demonstrated the resilience of Burjeel Holdings’ integrated healthcare platform,” Dr Vayalil said.
“Despite a challenging regional backdrop, we maintained uninterrupted care, delivered solid financial performance, and continued to invest in our clinical capabilities, community-based network, and digital infrastructure,” he said.
Dr Vayalil said accelerating patient activity during the second quarter reinforced the company’s confidence in structural demand for specialised healthcare across the region.
“Looking ahead, we remain focused on delivering sustainable value through investment in advanced clinical care, research, medical education, digital transformation, and AI-enabled healthcare,” he said.
